



Baptist Health South Florida

Continuing Medical Education

DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty members have indicated that they do not have any relevant financial relationships with ineligible companies* to disclose. **Indicates that this individual's presentation(s) **will include** discussion of off-label or unapproved usage.

Guenther Koehne, M.D., Ph.D.

The following faculty members have indicated that they do have relevant financial relationships with ineligible companies* to disclose.

The following faculty members have indicated that they do have relevant relationships with ineligible companies:

Adam D. Cohen, M.D., has indicated that he is a consultant/adviser or board member with Janssen, Glaxo Smith Kline, BMS/Celgene, Takeda, Oncoceptides, AstraZeneca, Genentech/Roche and Seattle Genetics.

Paul Lin, M.D., has indicated that he has received grant/research support from Takeda and other financial or material support from royalties from Takeda.

Paul G. Richardson, M.D. has indicated that he has received grant/research support from Oncoceptides, Celgene/BMS and Takeda. He is also a consultant/advisor or board member with Karyopharm, Janssen, Sanofi, SecuraBio and GSK.

Robert Sackstein, M.D. has indicated that he is an employee/owner and shareholder of Warrior Therapeutics, LLC. He also owns intellectual property released to GPS.

Robert Soiffer, M.D. has indicated that he is a consultant with Gilead, Rheos Therapeutics, VOR Biopharma and Novartis; and is on the board of Data Safety Monitoring Board for Juno/Celgene, Kiadis and Be The Match/National Marrow Donor Program.

Wendy Stock, M.D. has indicated that she is a consultant with Agios, Astellas, Kits, Daiichi and Amgen. She has received grant/research support from Pfizer and has received speaker honorariums for research to practice and up to date.

Richard M. Stone, M.D. has indicated that he is a consultant with Actinium, Arog, Jazz, Abbvie, Takeda, Elevate Bio, Syndax Pharma, Syros, Gemoab, BerGenGio, Froghorn Thera, GSK, Aprea, Innate, OncNova. He is also on the steering committee with Abbvie and on the data safety monitoring board with Takeda and Synrix/ACI Clinical.

All of the relevant financial relationships listed for these individuals have been mitigated.

Other individuals involved in planning, content review, approval, or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies*.

**Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*